Regional and international cooperation informing patient safety in Oman

Around the world / 23 October 2019

Since achieving full membership of the WHO Programme for International Drug Monitoring (PIDM) in 1996, Oman has steadily built an active, well-respected national centre.

Oman has established itself as one of the regional leaders in pharmacovigilance. Two recent events highlight its place on the regional and international stage. From 24 to 25 April this year, the First Oman Pharmacovigilance Symposium and annual QPPV meeting brought marketing authorisation holders (MAH), Middle East regulators, and other stakeholders together in Muscat. A key objective of the symposium was to ensure an open communication channel between regulators and Qualified Persons Responsible for Pharmaco­vigilance (QPPVs) from the MAH community and, in turn, to discuss topics of interest to the pharmacovigilance community.

The symposium was held under the auspices of H.E. Dr. Mohammed bin Saif Al Hosni, Undersecretary for Health Affairs, Ministry of Health, Oman, who remarked on the “importance of pharmacovigilance as seen in today’s social media platforms and its impact on online trading of medicines and health products”.

Representatives from the regulators of all the Gulf Cooperation Council countries and other regional stakeholders – Iraq, Jordan, Egypt, and Afghanistan – attended the symposium, underscoring its significance. In addition, Deliana Aboka and Magnus Ekelo represented the UMC and Dr. Houda Sefiani attended on behalf of Centre Anti Poison et de Pharmacovigilance du Maroc, the WHO Collaborating Centre for Strength-ening Pharmacovigilance Practices, Morocco. Of note, Aboka presented an update on VigiFlow and conducted a workshop on the pharmacovigilance focal points in Oman, and Houda discussed safety signal management and causality assessment. Another highlight of the symposium was a meeting with the QPPVs from the MAH community, where the floor was opened for a frank discussion with the regulatory authority’s pharmacovigilance team.

Oman has for some time been an active participant in work led by the Netherlands Pharmacovigilance Centre Lareb on incorporating pharmacovigilance in medical, dental, pharmaceutical, and nursing education.

This collaboration led to a visit by Lareb’s Dr. Linda Härmark to Oman, facilitated by the WHO country office Oman, as a temporary adviser.

The WHO country office in Oman facilitated a visit by Lareb’s Dr. Linda Härmark, front row, second from left. Photo: Ministry of Health, Oman

The WHO country office in Oman facilitated a visit by Lareb’s Dr. Linda Härmark, front row, second from left. Photo: Ministry of Health, Oman

Hussain Al Ramimmy
Pharmacovigilance & Drug Information, Ministry of Health, Oman

You may also like

Developing a pharmacovigilance system in the Instituto Nacional de Cardiología Ignacio Chávez at Mexico City

Undaunted by the pandemic, the team at Instituto Nacional de Cardiología Ignacio Chávez (Mexico) established a PV centre and a follow-up unit with direct, daily clinical impact.

Around the world / 10 February 2022

Evolution of pharmacovigilance in the Kingdom of Eswatini

Eswatini may be a small country, but its National Pharmacovigilance Centre has big ambitions that, with support from the PAVIA project, are quickly translating into achievements.

Around the world / 04 February 2022

EMA module on pregnancy prevention programmes and other pregnancy-specific risk minimisation

EMA has launched a public consultation on a new guidance: the EU-GVP Module XVI ADD III on pregnancy and other pregnancy-specific risk minimisation.

Around the world / 29 April 2022

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more